ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck

July 11, 2016

  • Tweet
  • Email
Print-Friendly Version

A new immunotherapy doubles overall survival and improves quality of life with fewer side effects in previously treated metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), according to a large, randomized international trial.

You Might Also Like

No related posts.

The findings are from the international CheckMate-141 clinical trial, and were presented in June at the American Society of Clinical Oncology annual meeting.

“These exciting results indicate that there is a new standard of care option for a population of head and neck cancer patients with no other treatment options,” said Robert Ferris, MD, PhD, chief of the division of head and neck surgery and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, and the trial’s international co-chair.

The new drug, nivolumab, an immunotherapeutic, currently is approved to treat some types of cancers, including melanoma and lung cancer.

The phase III study enrolled 361 patients with recurrent or metastatic SCCHN who had not responded to platinum-based chemotherapy. Patients were randomized to receive either nivolumab or a single type of standard chemotherapy until tumor progression was observed. The median overall survival (OS) with nivolumab was 7.5 months compared with 5.1 months with investigator’s choice (HR, 0.70; 95% CI, 0.51-0.96; P = .0101). The objective response rate (ORR) was 13.3% with nivolumab and 5.8% for investigator’s choice. After 12 months, 36% of the nivolumab group was alive, compared with 17% of the standard chemotherapy group.

Additionally, nivolumab appeared to be most successful in patients with tumors positive for human papillomavirus (HPV).

The trial was funded by the drug manufacturer, Bristol-Myers Squibb, which is now seeking FDA approval for the use of nivolumab in head and neck carcinoma.

Filed Under: Head and Neck, Online Exclusives, Practice Focus Tagged With: HNSCC, squamous cell carcinoma

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Some Studies Predict a Shortage of Otolaryngologists. Do the Numbers Support Them?
    • Vertigo in the Elderly: What Does It Mean?
    • Complications for When Physicians Change a Maiden Name
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Tympanoplasty Tips: Otology Experts Give Advice on the Procedure
    • How Treatment for Obstructive Sleep Apnea (OSA) Is Evolving to Give Patients a Better Night’s Sleep
    • Vestibular Schwannoma Position Relative to Internal Auditory Canal Helps Predict Postoperative Facial Function
    • Vocal Fold Lipoaugmentation Provides Long-Term Voice Improvements for Glottal Insufficiency
    • Upper Lateral Cartilage Mucosal Flap Enables the Successful Closure of Larger Septal Perforations

Polls

Do you think there will be a shortage of otolaryngologists in the next five to 10 years?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.